Aileron Therapeutics (NASDAQ: ALRN) announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in p53-mutated breast cancer showed severe neutropenia (Grade 4) and alopecia (hair loss).
The primary endpoint of the Phase 1b open-label trial was evaluating ALRN-6924 in patients with breast cancer receiving neoadjuvant or adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide, or "TAC" chemotherapy, was the duration and incidence of severe neutropenia in cycle 1.
The incidence of chemotherapy-induced alopecia (hair loss) was a secondary endpoint.
Based on these findings, Aileron has decided to terminate the Phase 1b breast cancer trial and further development of ALRN-6924.
Aileron also announced that it is exploring various strategic alternatives and has engaged Ladenburg Thalmann & Co Inc as a strategic advisor for this process.
Aileron will reduce its remaining workforce from 9 to 3 full-time employees in the coming weeks. The company plans to retain the remaining employees to assist in executing the strategic alternatives review process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.